Days after the Food and Drug Administration (FDA) issued a Public Notification warning consumers not to purchase or use A1 Slim diet pills because they contained hidden drugs that posed a risk to some consumers, the dietary supplement’s manufacturer, Kiriko LLC, issued a recall of all lots of A1 Slim capsules.
A laboratory analysis conducted by the FDA first revealed the diet pills contained sibutramine. Later, the FDA found that the capsules also contained phenolphthalein and N-Desmethyl sibutramine.
Sibutramine is an appetite suppressant that was withdrawn from the U.S. market in October 2010 due to safety concerns. N0Desmethyl sibutramine is an active metabolite of sibutramine. Sibutramine and its active metabolites substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. Phenolphthalein was previous used in over-the counter laxatives but is no longer on the market due to concerns that it carried a cancer risk.
To date, Kiriko has not received any reports of adverse events.
A1 Slim is promoted as a weight loss supplement and is packaged in white plastic bottles, each containing 30 capsules. The bottles have a white screw-on cap and the barcode A105212014. The diet pills were distributed nationwide through retail stores in Houston, Texas, and by mail-order from Dec. 6, 2016, through May 1, 2017.
Anyone with A1 Slim diet pills in their possession should stop using them immediately and contact their doctor if they are experiencing any health issues. Adverse events and side effects related to use of this drug should be reported to the FDA MedWatch Adverse Event Reporting Program at www.FDA.gov/MedWatch/Report.htm.
FDA Recall Notice